The effect of managed care on prescription drug costs and benefits

被引:23
作者
Lyles, A [1 ]
Palumbo, FB [1 ]
机构
[1] Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA
关键词
D O I
10.2165/00019053-199915020-00002
中图分类号
F [经济];
学科分类号
02 ;
摘要
This review discusses the approaches to prescription drug payment practices taken by managed care to influence drug use and costs, and presents the research evidence supporting these interventions. In the US, drugs were infrequently covered as an ambulatory benefit under fee-for-service indemnity insurance; however, health maintenance organisations almost always provide outpatient drugs and consequently have developed approaches to influence drug use and manage its costs. Managed care as a set of tools and as an organisational form is moving toward more restrictions on direct access to pharmaceuticals as a covered benefit. Options for influencing drug use and cost may address access, ingredient costs, dispensing fees and cost sharing. The formulary process is the foundation for a managed pharmacy benefit and integrates these options. The limited empirical evidence for an effect of managed care on drug costs and use is reviewed. A proposed research agenda includes evaluation of the effects of restrictive formularies, capitation, disease management and other programmes to influence the cost and use of pharmaceuticals.
引用
收藏
页码:129 / 140
页数:12
相关论文
共 90 条
  • [1] Adams EK, 1996, INQUIRY-J HEALTH CAR, V33, P339
  • [2] Disease management programs
    Armstrong, EP
    Langley, PC
    [J]. AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 1996, 53 (01) : 53 - 58
  • [3] Blissenbach H. F., 1996, MANAGED CARE HDB, P367
  • [4] BROWN L, 1998, EVOLUTION MANAGED S1, V14, P37
  • [5] *BUR LAB STAT, 1997, PPI PHARM PREP 2834
  • [6] *C BUDG OFF, 1996, CBO PAP MED REB PRES
  • [7] CAPITATED MEDICAID AND THE PROCESS OF CARE OF ELDERLY HYPERTENSIVES AND DIABETICS - RESULTS FROM A RANDOMIZED TRIAL
    COFFEY, E
    MOSCOVICE, I
    FINCH, M
    CHRISTIANSON, JB
    LURIE, N
    [J]. AMERICAN JOURNAL OF MEDICINE, 1995, 98 (06) : 531 - 536
  • [8] What does treatment of depression really cost?
    Croghan, TW
    Obenchain, RL
    Crown, WE
    [J]. HEALTH AFFAIRS, 1998, 17 (04) : 198 - 208
  • [9] Pharmacoeconomic studies - Pitfalls and problems
    DeGraeve, D
    Nonneman, W
    [J]. INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 1996, 12 (01) : 22 - 30
  • [10] Comorbidity measures for use with administrative data
    Elixhauser, A
    Steiner, C
    Harris, DR
    Coffey, RN
    [J]. MEDICAL CARE, 1998, 36 (01) : 8 - 27